MENU
BMED
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

BMED stock forecast, quote, news & analysis

The investment seeks to maximize total return... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
BMED
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BMED with price predictions
Oct 23, 2026

BMED in +3.13% Uptrend, growing for three consecutive days on October 21, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BMED advanced for three days, in 225 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on BMED as a result. In 76 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for BMED just turned positive on October 15, 2026. Looking at past instances where BMED's MACD turned positive, the stock continued to rise in 33 of 44 cases over the following month. The odds of a continued upward trend are 75%.

The Aroon Indicator entered an Uptrend today. In 215 of 281 cases where BMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

BMED broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Moderna (NASDAQ:MRNA), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The investment seeks to maximize total return. Under normal market conditions, the fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. While the fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants.

Market Cap

The average market capitalization across the iShares Health Innovation Active ETF (BMED) ETF is 47.88B. The market cap for tickers in the group ranges from 371.66M to 635.76B. JNJ holds the highest valuation in this group at 635.76B. The lowest valued company is AVTX at 371.66M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Health Innovation Active ETF (BMED) ETF was 2%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 25%. SGMT experienced the highest price growth at 19%, while AVTX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the iShares Health Innovation Active ETF (BMED) ETF was -16%. For the same stocks of the ETF, the average monthly volume growth was -13% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 44
Price Growth Rating: 47
SMR Rating: 78
Profit Risk Rating: 77
Seasonality Score: 19 (-100 ... +100)